VVOS Stock Forecast: Vivos Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Vivos Therapeutics, Inc. is $1.93. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Vivos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (77): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VVOS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VVOS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 16 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 June 2026 | Ascendiant Capital | Maintains | Buy | $3.00 → $3.10 |
| 22 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 17 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Apr 2026 | HC Wainwright& Co. | Maintains | Buy | — |
| 3 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 17 Nov 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 9 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 15 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 20 Nov 2024 | Ascendiant Capital | Reiterates | Buy | — |
| 19 Nov 2024 | Alliance Global Partners | Maintains | Buy | — |
| 20 Aug 2024 | Ascendiant Capital | Maintains | Buy | — |
| 17 Jan 2023 | Ascendiant Capital | Initiates | Buy | $2.50 |
| 13 Aug 2021 | Roth Capital | Maintains | Buy | $11 → $10 |
| 18 May 2021 | Roth Capital | Maintains | Buy | $12 → $11 |
| 11 Jan 2021 | Craig-Hallum | Initiates | Buy | — |
| 5 Jan 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VVOS.
This page is one stock. Monday covers all of them.
VVOS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VVOS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Vivos Therapeutics, Inc. returned −97.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VVOS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.1×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 95% of US stocks
- Revenue growth (YoY)
- 34.9%
- Earnings growth (YoY)
- —
- Gross margin
- 57.3%
- Operating margin
- —
- Net margin
- —
Higher than 80% of US stocks
Higher than 70% of US stocks
- Return on equity
- —
- Return on assets
- −56.2%
- Dividend yield
- —
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vivos Therapeutics, Inc. has a market value of $1.9M and an enterprise value of $13.3M.
Revenue in the twelve months to 30 June 2026: $20.9M. The latest quarter grew 34.9% year on year.
Net income over the same four quarters: −$25.6M, a −122.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$19.0M.
Vivos Therapeutics, Inc. employs 268 people — $78K of revenue per employee.
Data provided by Twelve Data
VVOS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VVOS’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Vivos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VVOS
What is the VVOS stock price forecast for 2026-2027?
The median 12-month analyst price target for Vivos Therapeutics, Inc. is $1.93, with estimates ranging from $0.75 to $3.1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VVOS stock a buy right now?
Of the 2 analysts covering Vivos Therapeutics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivos Therapeutics, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VVOS?
As at 21 Nov 2026, Vivos Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (77 of 100).
Will VVOS stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $1.93, and Ticker Nerd's factor model ranks Vivos Therapeutics, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VVOS stock forecast for 2030?
No analyst covering Vivos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VVOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.75 to $3.1 over the next 12 months.
How has VVOS stock performed over the past year?
Vivos Therapeutics, Inc. returned -97.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Vivos Therapeutics, Inc. do?
Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on addressing dentofacial abnormalities, obstructive sleep apnea, and snoring through non-invasive treatment solutions. The company develops and commercializes the Vivos Method, an oral appliance-based approach used by trained dental and medical professionals to support airway health and sleep wellness.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on addressing dentofacial abnormalities, obstructive sleep apnea, and snoring through non-invasive treatment solutions. The company develops and commercializes the Vivos Method, an oral appliance-based approach used by trained dental and medical professionals to support airway health and sleep wellness. Its current offerings also include the VivoScore Program, which provides screening and home sleep testing for adults and children, along with related appliances, treatment protocols, and support services. Vivos Therapeutics works primarily with licensed professionals, especially general dentists, in the United States and Canada, positioning its products within the broader sleep-disordered breathing and oral appliance therapy markets. Based in Littleton, Colorado, the company serves as a specialized provider in the healthcare technology sector.
CEO Mr. R. Kirk Huntsman · 268 employees · United States · https://www.vivos.com